Downloads: 1
Diff of
/html_files/24518095.html
[000000]
..
[c0f169]
Switch to unified view
| a | b/html_files/24518095.html | ||
|---|---|---|---|
| 1 | |||
| 2 | <!DOCTYPE html> |
||
| 3 | <html> |
||
| 4 | <head> |
||
| 5 | <meta charset="utf-8"> |
||
| 6 | <title>24518095 Visualization</title> |
||
| 7 | </head> |
||
| 8 | <body> |
||
| 9 | <h1>24518095 Visualization</h1> |
||
| 10 | <p><a href="main.html">Back to Main Page</a></p> |
||
| 11 | <div class="entities" style="line-height: 2.5; direction: ltr">A |
||
| 12 | <mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 13 | 44 |
||
| 14 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
||
| 15 | </mark> |
||
| 16 | - |
||
| 17 | <mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 18 | year |
||
| 19 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
||
| 20 | </mark> |
||
| 21 | - |
||
| 22 | <mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 23 | old |
||
| 24 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
||
| 25 | </mark> |
||
| 26 | |||
| 27 | <mark class="entity" style="background: #a0ced9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 28 | Chinese |
||
| 29 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Personal_background</span> |
||
| 30 | </mark> |
||
| 31 | |||
| 32 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 33 | man |
||
| 34 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sex</span> |
||
| 35 | </mark> |
||
| 36 | with a |
||
| 37 | <mark class="entity" style="background: #e2f0cb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 38 | 7 |
||
| 39 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">History</span> |
||
| 40 | </mark> |
||
| 41 | |||
| 42 | <mark class="entity" style="background: #e2f0cb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 43 | pack |
||
| 44 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">History</span> |
||
| 45 | </mark> |
||
| 46 | - |
||
| 47 | <mark class="entity" style="background: #e2f0cb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 48 | year |
||
| 49 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">History</span> |
||
| 50 | </mark> |
||
| 51 | |||
| 52 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 53 | smoking |
||
| 54 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Activity</span> |
||
| 55 | </mark> |
||
| 56 | |||
| 57 | <mark class="entity" style="background: #e2f0cb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 58 | history |
||
| 59 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">History</span> |
||
| 60 | </mark> |
||
| 61 | was |
||
| 62 | <mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 63 | referred |
||
| 64 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
||
| 65 | </mark> |
||
| 66 | to |
||
| 67 | <mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 68 | Shanghai |
||
| 69 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span> |
||
| 70 | </mark> |
||
| 71 | |||
| 72 | <mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 73 | Pulmonary |
||
| 74 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span> |
||
| 75 | </mark> |
||
| 76 | |||
| 77 | <mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 78 | Hospital |
||
| 79 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span> |
||
| 80 | </mark> |
||
| 81 | in |
||
| 82 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 83 | February |
||
| 84 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 85 | </mark> |
||
| 86 | |||
| 87 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 88 | 2013 |
||
| 89 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 90 | </mark> |
||
| 91 | for a |
||
| 92 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 93 | left |
||
| 94 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 95 | </mark> |
||
| 96 | |||
| 97 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 98 | upper |
||
| 99 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 100 | </mark> |
||
| 101 | |||
| 102 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 103 | lobe |
||
| 104 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 105 | </mark> |
||
| 106 | |||
| 107 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 108 | lung |
||
| 109 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 110 | </mark> |
||
| 111 | |||
| 112 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 113 | mass |
||
| 114 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 115 | </mark> |
||
| 116 | with |
||
| 117 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 118 | multiple |
||
| 119 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 120 | </mark> |
||
| 121 | |||
| 122 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 123 | bilateral |
||
| 124 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 125 | </mark> |
||
| 126 | |||
| 127 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 128 | intrapulmonary |
||
| 129 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 130 | </mark> |
||
| 131 | |||
| 132 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 133 | metastases |
||
| 134 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 135 | </mark> |
||
| 136 | , |
||
| 137 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 138 | left |
||
| 139 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 140 | </mark> |
||
| 141 | |||
| 142 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 143 | pleural |
||
| 144 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 145 | </mark> |
||
| 146 | |||
| 147 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 148 | effusion |
||
| 149 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 150 | </mark> |
||
| 151 | , and |
||
| 152 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 153 | 2R/4R/10L/11L |
||
| 154 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 155 | </mark> |
||
| 156 | |||
| 157 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 158 | lymphadenopathy |
||
| 159 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 160 | </mark> |
||
| 161 | .</br> |
||
| 162 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 163 | Pleural |
||
| 164 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 165 | </mark> |
||
| 166 | |||
| 167 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 168 | fluid |
||
| 169 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 170 | </mark> |
||
| 171 | |||
| 172 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 173 | cytology |
||
| 174 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 175 | </mark> |
||
| 176 | revealed |
||
| 177 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 178 | adenocarcinoma |
||
| 179 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 180 | </mark> |
||
| 181 | and |
||
| 182 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 183 | Scorpion |
||
| 184 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 185 | </mark> |
||
| 186 | |||
| 187 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 188 | Amplification |
||
| 189 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 190 | </mark> |
||
| 191 | |||
| 192 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 193 | Refractory |
||
| 194 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 195 | </mark> |
||
| 196 | |||
| 197 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 198 | Mutation |
||
| 199 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 200 | </mark> |
||
| 201 | |||
| 202 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 203 | system |
||
| 204 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 205 | </mark> |
||
| 206 | ( |
||
| 207 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 208 | AmoyDx |
||
| 209 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 210 | </mark> |
||
| 211 | |||
| 212 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 213 | Co., |
||
| 214 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 215 | </mark> |
||
| 216 | |||
| 217 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 218 | Xiamen, |
||
| 219 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 220 | </mark> |
||
| 221 | |||
| 222 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 223 | China |
||
| 224 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 225 | </mark> |
||
| 226 | ).</br>showed no detectable |
||
| 227 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 228 | epidermal |
||
| 229 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 230 | </mark> |
||
| 231 | |||
| 232 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 233 | growth |
||
| 234 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 235 | </mark> |
||
| 236 | |||
| 237 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 238 | factor |
||
| 239 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 240 | </mark> |
||
| 241 | |||
| 242 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 243 | receptor |
||
| 244 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 245 | </mark> |
||
| 246 | |||
| 247 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 248 | mutation |
||
| 249 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 250 | </mark> |
||
| 251 | .</br>He commenced |
||
| 252 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 253 | chemotherapy |
||
| 254 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 255 | </mark> |
||
| 256 | with |
||
| 257 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 258 | gemcitabine |
||
| 259 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 260 | </mark> |
||
| 261 | and |
||
| 262 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 263 | cisplatin |
||
| 264 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 265 | </mark> |
||
| 266 | .</br>However, after a single cycle, his |
||
| 267 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 268 | symptoms |
||
| 269 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 270 | </mark> |
||
| 271 | worsened and imaging confirmed |
||
| 272 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 273 | progressive |
||
| 274 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 275 | </mark> |
||
| 276 | |||
| 277 | <mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 278 | disease |
||
| 279 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
||
| 280 | </mark> |
||
| 281 | .</br>A |
||
| 282 | <mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 283 | second |
||
| 284 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
||
| 285 | </mark> |
||
| 286 | |||
| 287 | <mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 288 | opinion |
||
| 289 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
||
| 290 | </mark> |
||
| 291 | |||
| 292 | <mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 293 | was |
||
| 294 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
||
| 295 | </mark> |
||
| 296 | |||
| 297 | <mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 298 | requested |
||
| 299 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
||
| 300 | </mark> |
||
| 301 | from the |
||
| 302 | <mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 303 | University |
||
| 304 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span> |
||
| 305 | </mark> |
||
| 306 | |||
| 307 | <mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 308 | of |
||
| 309 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span> |
||
| 310 | </mark> |
||
| 311 | |||
| 312 | <mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 313 | Colorado |
||
| 314 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span> |
||
| 315 | </mark> |
||
| 316 | and a |
||
| 317 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 318 | computed |
||
| 319 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 320 | </mark> |
||
| 321 | |||
| 322 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 323 | tomography |
||
| 324 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 325 | </mark> |
||
| 326 | – |
||
| 327 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 328 | guided |
||
| 329 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 330 | </mark> |
||
| 331 | |||
| 332 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 333 | biopsy |
||
| 334 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 335 | </mark> |
||
| 336 | of the |
||
| 337 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 338 | left |
||
| 339 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 340 | </mark> |
||
| 341 | |||
| 342 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 343 | upper |
||
| 344 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 345 | </mark> |
||
| 346 | |||
| 347 | <mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 348 | lobe |
||
| 349 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
||
| 350 | </mark> |
||
| 351 | |||
| 352 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 353 | lesion |
||
| 354 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 355 | </mark> |
||
| 356 | was performed to permit additional molecular testing.</br>In the interim, the patient commenced |
||
| 357 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 358 | pemetrexed |
||
| 359 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 360 | </mark> |
||
| 361 | and |
||
| 362 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 363 | nedaplatin |
||
| 364 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 365 | </mark> |
||
| 366 | .</br>Unfortunately, after two cycles his |
||
| 367 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 368 | shortness |
||
| 369 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 370 | </mark> |
||
| 371 | |||
| 372 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 373 | of |
||
| 374 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 375 | </mark> |
||
| 376 | |||
| 377 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 378 | breath |
||
| 379 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 380 | </mark> |
||
| 381 | worsened, with evidence of |
||
| 382 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 383 | further |
||
| 384 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 385 | </mark> |
||
| 386 | |||
| 387 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 388 | progression |
||
| 389 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 390 | </mark> |
||
| 391 | on his |
||
| 392 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 393 | scans |
||
| 394 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 395 | </mark> |
||
| 396 | (Fig.1A).</br>Molecular testing on his repeat |
||
| 397 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 398 | biopsy |
||
| 399 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 400 | </mark> |
||
| 401 | specimen revealed no |
||
| 402 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 403 | mutations |
||
| 404 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 405 | </mark> |
||
| 406 | by |
||
| 407 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 408 | SNaPshot |
||
| 409 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 410 | </mark> |
||
| 411 | |||
| 412 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 413 | multiplex |
||
| 414 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 415 | </mark> |
||
| 416 | |||
| 417 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 418 | PCR |
||
| 419 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 420 | </mark> |
||
| 421 | |||
| 422 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 423 | testing |
||
| 424 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 425 | </mark> |
||
| 426 | (Life Technologies, Carlsbad, CA).</br>However, although technically negative, the |
||
| 427 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 428 | ALK |
||
| 429 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 430 | </mark> |
||
| 431 | |||
| 432 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 433 | break |
||
| 434 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 435 | </mark> |
||
| 436 | - |
||
| 437 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 438 | apart |
||
| 439 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 440 | </mark> |
||
| 441 | |||
| 442 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 443 | FISH |
||
| 444 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 445 | </mark> |
||
| 446 | |||
| 447 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 448 | test |
||
| 449 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 450 | </mark> |
||
| 451 | showed an |
||
| 452 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 453 | atypical |
||
| 454 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 455 | </mark> |
||
| 456 | |||
| 457 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 458 | negative |
||
| 459 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 460 | </mark> |
||
| 461 | |||
| 462 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 463 | pattern |
||
| 464 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 465 | </mark> |
||
| 466 | .</br>Specifically, |
||
| 467 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 468 | 68% |
||
| 469 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 470 | </mark> |
||
| 471 | |||
| 472 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 473 | of |
||
| 474 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 475 | </mark> |
||
| 476 | |||
| 477 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 478 | cells |
||
| 479 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 480 | </mark> |
||
| 481 | |||
| 482 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 483 | demonstrated |
||
| 484 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 485 | </mark> |
||
| 486 | |||
| 487 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 488 | single |
||
| 489 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 490 | </mark> |
||
| 491 | |||
| 492 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 493 | copies |
||
| 494 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 495 | </mark> |
||
| 496 | |||
| 497 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 498 | of |
||
| 499 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 500 | </mark> |
||
| 501 | |||
| 502 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 503 | the |
||
| 504 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 505 | </mark> |
||
| 506 | |||
| 507 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 508 | 5′ |
||
| 509 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 510 | </mark> |
||
| 511 | |||
| 512 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 513 | ALK |
||
| 514 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 515 | </mark> |
||
| 516 | |||
| 517 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 518 | signal |
||
| 519 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 520 | </mark> |
||
| 521 | and |
||
| 522 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 523 | numerous |
||
| 524 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 525 | </mark> |
||
| 526 | |||
| 527 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 528 | cells |
||
| 529 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 530 | </mark> |
||
| 531 | |||
| 532 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 533 | with |
||
| 534 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 535 | </mark> |
||
| 536 | |||
| 537 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 538 | doublets |
||
| 539 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 540 | </mark> |
||
| 541 | |||
| 542 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 543 | of |
||
| 544 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 545 | </mark> |
||
| 546 | |||
| 547 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 548 | the |
||
| 549 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 550 | </mark> |
||
| 551 | |||
| 552 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 553 | 5′ |
||
| 554 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 555 | </mark> |
||
| 556 | |||
| 557 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 558 | ALK |
||
| 559 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 560 | </mark> |
||
| 561 | |||
| 562 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 563 | signal |
||
| 564 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 565 | </mark> |
||
| 566 | |||
| 567 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 568 | combined |
||
| 569 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 570 | </mark> |
||
| 571 | |||
| 572 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 573 | with |
||
| 574 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 575 | </mark> |
||
| 576 | |||
| 577 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 578 | one |
||
| 579 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 580 | </mark> |
||
| 581 | |||
| 582 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 583 | 3′ |
||
| 584 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 585 | </mark> |
||
| 586 | |||
| 587 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 588 | ALK |
||
| 589 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 590 | </mark> |
||
| 591 | |||
| 592 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 593 | signal |
||
| 594 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 595 | </mark> |
||
| 596 | (Fig.2A).</br>Subsequently, confirmatory |
||
| 597 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 598 | diagnostic |
||
| 599 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 600 | </mark> |
||
| 601 | |||
| 602 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 603 | assays |
||
| 604 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 605 | </mark> |
||
| 606 | demonstrated |
||
| 607 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 608 | ALK |
||
| 609 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 610 | </mark> |
||
| 611 | |||
| 612 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 613 | protein |
||
| 614 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 615 | </mark> |
||
| 616 | |||
| 617 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 618 | expression |
||
| 619 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 620 | </mark> |
||
| 621 | by |
||
| 622 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 623 | IHC |
||
| 624 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 625 | </mark> |
||
| 626 | using the |
||
| 627 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 628 | D5F3 |
||
| 629 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 630 | </mark> |
||
| 631 | |||
| 632 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 633 | antibody |
||
| 634 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 635 | </mark> |
||
| 636 | ( |
||
| 637 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 638 | Cell |
||
| 639 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 640 | </mark> |
||
| 641 | |||
| 642 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 643 | Signaling |
||
| 644 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 645 | </mark> |
||
| 646 | |||
| 647 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 648 | Technology |
||
| 649 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 650 | </mark> |
||
| 651 | |||
| 652 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 653 | Inc., |
||
| 654 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 655 | </mark> |
||
| 656 | |||
| 657 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 658 | Danvers, |
||
| 659 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 660 | </mark> |
||
| 661 | |||
| 662 | <mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 663 | MA |
||
| 664 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
||
| 665 | </mark> |
||
| 666 | ; H score = 150; Fig.2B) and the |
||
| 667 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 668 | presence |
||
| 669 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 670 | </mark> |
||
| 671 | |||
| 672 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 673 | of |
||
| 674 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 675 | </mark> |
||
| 676 | |||
| 677 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 678 | an |
||
| 679 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 680 | </mark> |
||
| 681 | |||
| 682 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 683 | echinoderm |
||
| 684 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 685 | </mark> |
||
| 686 | |||
| 687 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 688 | microtubule |
||
| 689 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 690 | </mark> |
||
| 691 | - |
||
| 692 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 693 | associated |
||
| 694 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 695 | </mark> |
||
| 696 | |||
| 697 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 698 | protein |
||
| 699 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 700 | </mark> |
||
| 701 | - |
||
| 702 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 703 | like |
||
| 704 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 705 | </mark> |
||
| 706 | |||
| 707 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 708 | 4 |
||
| 709 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 710 | </mark> |
||
| 711 | (EML4)-ALK |
||
| 712 | <mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 713 | transcript |
||
| 714 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
||
| 715 | </mark> |
||
| 716 | (E13; A20) by |
||
| 717 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 718 | RT |
||
| 719 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 720 | </mark> |
||
| 721 | - |
||
| 722 | <mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 723 | PCR |
||
| 724 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
||
| 725 | </mark> |
||
| 726 | (Fig.2C).</br>The patient then received |
||
| 727 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 728 | crizotinib |
||
| 729 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 730 | </mark> |
||
| 731 | ( |
||
| 732 | <mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 733 | 250 |
||
| 734 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
||
| 735 | </mark> |
||
| 736 | |||
| 737 | <mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 738 | mg |
||
| 739 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
||
| 740 | </mark> |
||
| 741 | |||
| 742 | <mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 743 | twice |
||
| 744 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
||
| 745 | </mark> |
||
| 746 | |||
| 747 | <mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 748 | daily |
||
| 749 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
||
| 750 | </mark> |
||
| 751 | ) as third-line therapy in |
||
| 752 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 753 | May |
||
| 754 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 755 | </mark> |
||
| 756 | |||
| 757 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 758 | 2013 |
||
| 759 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 760 | </mark> |
||
| 761 | with an impressive |
||
| 762 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 763 | symptomatic |
||
| 764 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 765 | </mark> |
||
| 766 | |||
| 767 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 768 | improvement |
||
| 769 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 770 | </mark> |
||
| 771 | and CT response |
||
| 772 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 773 | after |
||
| 774 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 775 | </mark> |
||
| 776 | |||
| 777 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 778 | 1 |
||
| 779 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 780 | </mark> |
||
| 781 | |||
| 782 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 783 | month |
||
| 784 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 785 | </mark> |
||
| 786 | of therapy (Fig.1B).</br>He remains on treatment with |
||
| 787 | <mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 788 | crizotinib |
||
| 789 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
||
| 790 | </mark> |
||
| 791 | with no evidence of |
||
| 792 | <mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 793 | progression |
||
| 794 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
||
| 795 | </mark> |
||
| 796 | as of |
||
| 797 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 798 | September |
||
| 799 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 800 | </mark> |
||
| 801 | |||
| 802 | <mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
||
| 803 | 2013 |
||
| 804 | <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
||
| 805 | </mark> |
||
| 806 | .</br></div> |
||
| 807 | </body> |
||
| 808 | </html> |
||
| 809 |